Parexel

Jan 25, 2023

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Clinical research organization Parexel announced an agreement with MyEyeDr. to refer its eye care patients into clinical trials. The two are collaborating on recruiting patients for a diabetic retinopathy study, according to a press release from Parexel, and plan to expand into other areas, such as endocrinology. Parexel and MyEyeDr. will work together on recruiting eye care patients into clinical trials. Source: Adobe Stock As part of the agreement, MyEyeDr. and its 850 eye care practices will be a member of Parexel’s Community Alliance Network, which helps bring clinical research into the community health care setting. Clare Grace Clare Grace, PhD, Paraxel’s chief patient officer, told Healio that the clinical research organization works with biopharma leaders, emerging innovators and sites to offer clinical research opportunities. “This formal agreement with MyEyeDr. will allow us to meet patients where they already are, such as centers providing annual routine eye exams and other vision care, to make clinical research more accessible,” Grace said. “The goal is that through this agreement, we will be able to generate an increased awareness of clinical research as a whole and within the optometry space to increase our reach for clinical trial recruitment and, ultimately, speed the availability of life-changing treatments for patients.” Artis Beatty, OD, MS, chief medical officer at MyEyeDr., told Healio that the group is working with Parexel on the diabetic retinopathy study to offer alternative treatment options to patients with specific diabetic eye disease. “Participating in the DREAM study has been a phenomenal way to open our relationship because of the number of patients that we actively manage and co-manage that meet the study criteria,” Beatty said. “We have been able to develop a number of systems for tracking and reporting for this particular study that will become the basis for future involvement with Parexel on any number of other ventures.” In addition, Beatty said MyEyeDr. can offer the benefits of a multisite entity. “All our practices operate on shared systems,” Beatty said. “That means ... millions of patients can decide to participate in research, be screened for participation criteria and reliably have records and reporting centralized in ways never before seen or imagined. This collaboration emphasizes the role optometrists play in primary patient care and the importance of that role in investigational medicine.” Grace added, “The ultimate goal of our agreement with MyEyeDr. is to make clinical research a more accessible care option by leveraging MyEyeDr.’s vast community of patients.” Reference: Parexel teams with MyEyeDr. to increase patient access and participation in ophthalmology clinical trials. https://newsroom.parexel.com/news-releases/news-release-details/parexel-teams-myeyedr-increase-patient-access-and-participation . Posted Dec. 15, 2022. Accessed Jan. 24, 2023. Read more about